PhD. 1996 Rheumatology Unit, Royal Postgraduate Medical School

Studies of a human monoclonal antiphospholipid antibody

1996-2005 Department of Haematology, University of Cambridge. DNA based idiotypic vaccination as a treatment for follicular lymphoma, production of clinical grade patient specific DNA vaccines for a Phase I/II clinical trial. Prime-boost vaccination (DNA/MVA) as a treatment for follicular lymphoma. Molecular adjuvants and DNA vaccination. The use of DNA vaccination to produce domain/fragment specific antibodies. Antibody engineering.

AWARDS AND GRANTS 2002-05 Prime-Boost Vaccines For Chronic Myelogenous Leukaemia, The Lymphoma and Leukemia Society. Principal Investigator, with Dr W. H. Ouwehand, Prof. J. Melo and Dr J. Apperly $373,125

2001-04 Development of recombinant human antibodies against B7.1 (CD80) for immune tolerisation in haematopoietic stem cell transplantation, with Dr N.A. Watkins, Dr, Dr C. Navarrete and Prof. K. Wood, National Blood Service, 135,42

2001-03 DNA based idiotypic vaccination in Follicular Lymphoma, with Dr W.H. Ouwehand, Cancer Research Campaign/Cancer Research UK, 63,600

1998-2002 DNA based idiotypic vaccination in Follicular Lymphoma, with Dr W. H. Ouwehand, with Prof. Freda K. Stevenson and Prof. T. J. Hamblin, National Blood Service, 243,318

Antibody engineering and assay development. Specificity of lymphoma antibodies. Molecular characteristics of antibodies involved in heparin induced thrombocytopenia. DNA vaccination